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Abstract
Background: SIRT1 is a mammalian homologue of NAD+-dependent deacetylase sirtuin family. It
regulates longevity in several model organisms and is involved with cell survival, differentiation,
metabolism among other processes in mammalian cells. SIRT1 modulates functions of various key
targets via deacetylation. Recent studies have revealed SIRT1 protects neurons from axonal
degeneration or neurodegeneration. Further, SIRT1 null mice exhibit growth retardation and
developmental defects, suggesting its critical roles in neurons and development.
Results: To identify novel binding partners for SIRT1 in the central nervous system, we performed
yeast two-hybrid screening on human fetal brain cDNA library and found that zyxin is a possible
binding partner. SIRT1 and zyxin transcript were both preferentially expressed in developmental
mouse brain. Zyxin accumulates in the nucleus where it is co-localized with SIRT1 after treatment
with leptomycin B in COS-7 cells. Furthermore, SIRT1 deacetylates zyxin, suggesting SIRT1 could
interact with nuclear-accumulated zyxin and modulate its function through deacetylation.
Conclusion: Zyxin could be a novel interacting partner of SIRT1. Zyxin is an adaptor protein at
focal adhesion plaque, regulating cytoskeletal dynamics and signal transduction to convey signal
from the ECM (extracellular matrix) to the nucleus. Our results raise the possibility that SIRT1
regulates signal transmission from ECM to the nucleus by modulating the functions of zyxin via
deacetylation.
Background
SIRT1 is the mammalian homologue closest to yeast
NAD+-dependent deacetylase Sir2 (silent information
regulation 2). It was originally identified as a lifespan-
extending gene when over-expressed in budding yeast,
Caenorhabditis elegans, and Drosophila melanogaster [1-3].
There are seven homologues of SIRT (named SIRT1-7) in
mammals, and SIRT1 is the homologue closest to Sir2.
Post-translational modification of proteins, like acetyla-
tion, methylation, and phosphorylation, plays a pivotal
role in the biological functions [4,5]. Recently, several
lines of evidence have indicated that SIRT1 regulates vari-
ous functions such as cellular survival, differentiation,
and metabolism by modulating key targets via deacetyla-
Published: 27 January 2009
BMC Cell Biology 2009, 10:6 doi:10.1186/1471-2121-10-6
Received: 10 July 2008
Accepted: 27 January 2009
This article is available from: http://www.biomedcentral.com/1471-2121/10/6
© 2009 Fujita et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
Page 2 of 14
(page number not for citation purposes)
tion. These targets include FOXO, Ku70, p53, NF-κB,
PGC-1α (PPAR-gamma co-activator 1-alpha) and PPARγ
(peroxisome proliferator-activated receptor γ). [6-11]. The
knockout of SIRT1 is not embryonic lethal however most
null mice die in the perinatal period, exhibiting growth
retardation and developmental defects in various tissues
including eye, lung, pancreas, heart, and reproductive sys-
tem[12,13]. This indicates that SIRT1 plays a pivotal role
in the development of multiple organ systems. Further-
more, SIRT1 protects neuron from neurodegeneration in
cell-based models of Alzheimer's disease, amyotrophic
lateral sclerosis (ALS), and Wallerian degeneration [14-
16]. However, the molecular mechanism by which SIRT1
functions in the central nervous system (CNS) or in the
development remains unclear. In this study, to identify
interacting partners for SIRT1, we performed yeast two-
hybrid screening on human fetal brain cDNA library. We
found that zyxin is one of binding partners for SIRT1.
Zyxin is primarily localized at the focal adhesion plaque
complex as an adaptor protein [17,18]. Zyxin contains a
proline-rich domain at the N-terminus and three LIM
domains at the C-terminus that are cysteine-rich motifs
involved in protein-protein interactions. Zyxin interacts
with cytoskeleton-related proteins, including α-actinin,
Mena/VASP, CRP, and H-warts/LATS1 [19-22], and sign-
aling molecules, including Vav, CasL, and p130Cas
[23,24]. Focal adhesion plaques, where cells interact with
the extracellular matrix (ECM), form a structure where
multiple interactions and signal transduction networks
crosstalk. This not only regulates cell adhesion, spreading,
and motility but also transduces signals into the nucleus
to regulate gene expression, cell proliferation, differentia-
tion, and apoptosis [25,26]. LIM domain proteins, includ-
ing two related subfamily prototypes zyxin and paxillin,
have been implicated in the regulation of cytoskeletal
dynamics and signal transduction to convey signals from
the ECM to the nucleus at the focal adhesion plaques
[17,18]. It was recently reported that zyxin can shuttle
between the cytosol and the nucleus, where it could affect
transcriptional activity [27]. Furthermore, nuclear-accu-
mulated zyxin executes anti-apoptotic function in cooper-
ation with Akt in myocardiac cells [28,29].
Results
Identification of new binding partner for SIRT1
Human SIRT1 encodes 748 amino acids protein with a
nuclear localization signal (NLS) at the N-terminus (aa
41–46) and a sirtuin homology domain at the center (aa
261–447); this domain is a conserved catalytic domain
for deacetylation (Figure 1A). We performed yeast two-
hybrid screening on human fetal brain cDNA library.
SIRT1 is reported to perform functions by modulating var-
ious targets via deacetylation. We used the human SIRT1
aa 185–505 region, including the conserved sirtuin cata-
lytic domain, as bait. Through this screening, we found
several possible interacting partners for SIRT1 (data not
shown). Among them, five clones were identical to
human zyxin. Recent studies have shown that zyxin can
shuttle between the cytoplasm and the nucleus [30] and
that it performs anti-apoptotic function in the nucleus
[28,29]; these are characteristic features that zyxin shares
with SIRT1. Therefore, we decided to perform a functional
analysis to study the interaction between SIRT1 and zyxin.
Human zyxin encodes 572 amino acids protein with two
major domains: the N-terminal half domain including the
proline-rich region and nuclear export signal or nuclear
exclusive signal (NES) and three consecutive C-terminal
LIM domains (LIM1-3) (Figure 1B). Previous reports have
shown the binding regions for α-actinin, Ena/VASP, CRP,
and h-warts/LATS1 [19-22], as described in Figure 1B.
Since all identified zyxin clones in our screening con-
tained a C-terminal region and since the LIM domain was
implicated in protein-protein interaction, we conducted
mapping assays concentrating on the LIM domain of
zyxin. To map the precise region for zyxin to bind to
SIRT1, a yeast two-hybrid assay was performed using the
SIRT1 catalytic domain (aa 185–505) as bait and various
shorter zyxin fragments as prey. As shown in Figure 1C,
colonies appeared only when the yeast reporter line
(AH109) containing the SIRT1 catalytic domain was
transformed with the plasmid encoding the zyxin aa 176–
572 region on a 4-DO (drop out) medium lacking ade-
nine, histidine, leucin, and tryptophan. Furthermore,
these colonies exhibit LacZ+ phenotype on β-Gal assay,
indicating that the LIM3 domain (aa 501–572) is required
for binding to the SIRT1 catalytic domain. Interestingly,
we could not detect any colonies where the yeast reporter
line (AH109) containing the SIRT1 catalytic domain was
transformed with plasmid encoding full-length zyxin on a
4-DO medium. A previous study showed that full-length
zyxin interacts with h-warts/LATS1 in vivo but not in vitro,
raising the possibility that LIM1/2 domains are masked in
full-length zyxin and some modification might be critical
for their interaction [22]. Based on these data, the LIM3
domain is essential for the interaction between SIRT1 and
zyxin in yeast; however, we cannot rule out the possibility
that some modification might play a pivotal role for the
interaction in physiological conditions.
To further confirm the region of binding of zyxin to
SIRT1, we performed a pull-down assay using bacterially
expressed recombinant GST-SIRT1 and various fragments
of HA-tagged zyxin expressed in HEK293T cells (Figure
2A). The same amount of GST-SIRT1 fusion proteins
bound to glutathione sepharose beads was incubated with
various HA-tagged shorter zyxin fragments in vitro, and
the retained proteins were immunoblotted with anti-HA
antibody. As shown in the top panel in Figure 2B, weBMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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Interaction between SIRT1 and zyxin in yeast Figure 1
Interaction between SIRT1 and zyxin in yeast. (A) Schematic representations of SIRT1 are shown with the sirtuin 
homology domain. The bar below the SIRT1 structure shows the region used as the bait domain in the yeast two-hybrid sys-
tem. (B) Schematic diagram of zyxin and its deletion mutants are shown with their domain structures and representative bind-
ing partners. (C) In the yeast two-hybrid binding assay, the yeast reporter line (AH109) was co-transformed with plasmids 
encoding the SIRT1 catalytic domain and various zyxin deletion mutants on a 4-DO (drop out) medium. The line was photo-
graphed after 14 days of incubation.
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In vitro interaction of SIRT1 and zyxin Figure 2
In vitro interaction of SIRT1 and zyxin. (A) Diagram of zyxin full length (FL) and its various deletion mutants. (B) In vitro 
mapping of zyxin domains associates with SIRT1. HEK293T cells expressing the indicated zyxin-deletion mutant were lysed and 
the resulting lysates were incubated with GST-SIRT1 or control GST proteins immobilized on glutathione sepharose beads. 
Bound proteins were probed with anti-HA antibody. HA-zyxin or its mutants in lysates were revealed by immunoblotting with 
anti-HA antibody. The amounts of GST-SIRT1 and control GST proteins were revealed by amido black staining.
572 375 ∆2(hZyx 375-572 aa)
1 378 ∆1(hZyx 1-378 aa)
∆3(hZyx 375-503 aa)
375 503
572 444 ∆4(hZyx 444-572 aa)
∆5(hZyx 375-443 aa)
375 443
∆7(hZyx 504-572 aa)
572 504
503 444 ∆6(hZyx 444-503 aa)
A
FL(hZyx 1-572 aa)
LIM 1 LIM 2 LIM 3
NES Proline-rich
repeats
1
572
LIM domains
35
30
25
15
10
50
c
o
n
t
.
G
S
T
G
S
T
-
S
I
R
T
1 ∆2 ∆7 ∆6 ∆5 ∆4 ∆3
Pull-down: GST
WB: HA
Input: HA-zyxin
WB: HA
Input:GST, GST-SIRT1
Amidoblack staining
35
30
50
B
Lane
c
o
n
t
.
G
S
T
G
S
T
-
S
I
R
T
1
c
o
n
t
.
G
S
T
G
S
T
-
S
I
R
T
1
c
o
n
t
.
G
S
T
G
S
T
-
S
I
R
T
1
c
o
n
t
.
G
S
T
G
S
T
-
S
I
R
T
1
c
o
n
t
.
G
S
T
G
S
T
-
S
I
R
T
1
123456 789 1 0 1 1 1 2
kD
35
30
25
15BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
Page 5 of 14
(page number not for citation purposes)
could detect weak signals in lane 2 and strong signals in
lane 6, suggesting that GST-SIRT1 binds to hZyx 375–572
aa (Δ2) weakly and 444–572 aa (Δ4) strongly in vitro. We
found strong signals in lane 3 in the top panel in Figure
2B, indicating nonspecific binding for hZyx 375–503 aa
(Δ3) to GST and/or glutathione-sepharose beads. There-
fore, we could not assess the interaction between hZyx
375–503 aa (Δ3) and GST-SIRT1. We also could not assess
the interaction between SIRT1 and hZyx 444–503 (Δ6),
since we could detect no signals in lanes 9 and 10 in the
middle panel of Figure 2B. This suggested that hZyx 444–
503 (Δ6) protein might be unstable in HEK293T cells. In
addition, we found nonspecific binding of full-length
zyxin to GST and/or glutathione-sepharose beads and no
signals for the product of hZyx 1–378 aa (Δ1) (Additional
file 1), therefore we could not assess the interactions for
these proteins. Taken together, these results suggest that
zyxin interacts with SIRT1 directly in vitro and that the
LIM2-3 region of zyxin might be critical for binding to
SIRT1 in vitro, which is consistent with the result that the
LIM3 domain of zyxin is essential for binding to SIRT1 in
yeast.
Sub-cellular localization of SIRT1 and zyxin in COS-7 cells
Next, we examined the sub-cellular localization of SIRT1
and zyxin in mammalian cells by an immunocytochemis-
try assay. COS-7 cells were co-transfected with plasmids
expressing Myc-tagged SIRT1 and GFP-zyxin. As shown in
Figure 3A, SIRT1 is primarily localized in the nucleus with
a diffused pattern. GFP-zyxin, diffusedly localized in the
cytosol with some puncta, accumulates in the nucleus
after treatment with leptomycin B (LMB), an inhibitor of
CRM1-mediated nuclear exportation (Figure 3A). The
treatment with LMB induced the accumulation of GFP-
zyxin in the nucleus, where it is co-localized with SIRT1
(Figure 3A). To further confirm the co-localization
between SIRT1 and GFP-zyxin, we examined the co-local-
ization using ZX and ZY sections taken by scanning con-
focal microscopy. As in Figure 3B, Myc-tagged SIRT1 and
GFP-zyxin are clearly co-localized in the nucleus. We then
quantified the LMB-induced nuclear accumulation of
zyxin. LMB treatment remarkably increases the number of
COS-7 cells exhibiting nuclear-accumulated GFP-zyxin
(Figure 3C). Taken together, these results suggest that
zyxin, basically localized in the cytosol, translocates into
the nucleus, where it is co-localized with SIRT1 in COS-7
cells.
Interaction between SIRT1 and zyxin in mammalian cells
To confirm the interaction between SIRT1 and zyxin in
mammalian cells, we performed a co-immunoprecipita-
tion assay using HEK293T cells. HEK293T cells were tran-
siently co-transfected with expression vectors for HA-
tagged SIRT1 and GFP-zyxin individually or in combina-
tion, in the presence or absence of LMB. Cell lysates were
immunoprecipitated with anti-GFP or anti-HA antibody,
followed by Western blot analysis with a reciprocal anti-
body. HA-tagged SIRT1 was detected in the immunopre-
cipitates with anti-GFP antibody only in the presence of
LMB, but not in the absence of LMB (Figure 4A). Further-
more, GFP-zyxin was also detected in the immunoprecip-
itates with anti-HA antibody only in the presence of LMB,
but not in the absence of LMB (Figure 4B). These data sug-
gest that LMB induces the accumulation of GFP-zyxin in
the nucleus, leading to the interaction between HA-tagged
SIRT1 and GFP-zyxin probably in the nucleus. This is con-
sistent with our morphological data that indicate SIRT1
and zyxin are co-localized in the nucleus with LMB treat-
ment.
Next, to confirm the interaction between endogenous
SIRT1 and GFP-zyxin, we performed a co-immunoprecip-
itation assay using HEK292T cells expressing SIRT1
endogenously. HEK293T cells were transfected with GFP-
zyxin expressing plasmid, and cell lysates were immuno-
precipitated with anti-SIRT1 antibody or control IgG, fol-
lowed by Western blot analysis with anti-GFP antibody
(Figure 4C). GFP-zyxin was detected in the immunopre-
cipitates with anti-SIRT1 antibody, but not in those with
control IgG, indicating the interaction between endog-
enous SIRT1 and exogenously overexpressed GFP-zyxin.
Taken together, these results suggest that SIRT1 and zyxin,
both shuttling between cytosol and nucleus, could inter-
act primarily in the nucleus in HEK293T cells.
Expression profiles of SIRT1 and zyxin
To examine the expression profiles of SIRT1 and zyxin
transcript, we performed real-time PCR assay using total
RNAs derived from various adult mouse tissues. As shown
in Figure 5A, the expression pattern of zyxin transcript is
similar to that of SIRT1, with preferential expression in the
lung, spleen, and testis.
Then, to investigate the expression profile of SIRT1 and
zyxin transcript in the developmental brain, we per-
formed real-time PCR assay using total RNAs derived from
mouse brains at various developmental stages. The expres-
sion pattern of zyxin transcript in the developmental
brain is also similar to that of SIRT1, with preferential
expression at the E13-P1 stage (Figure 5B).
SIRT1 deacetylates zyxin in vitro and in vivo
SIRT1 is an NAD+-dependent protein deacetylase that tar-
gets a wide variety of proteins to modulate their functions
through deacetylation. Since we used the catalytic domain
of SIRT1 as bait in our screening, we sought to investigate
whether SIRT1 deacetylates zyxin. We first performed in
vitro  deacetylation assay using bacterially expressed
recombinant GST-SIRT1 and GFP-zyxin expressed in
HEK293T cells. Immunoprecipitated GFP-zyxin with anti-BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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Leptomycin B treatment causes nuclear accumulation of zyxin and results in co-localization of SIRT1 with zyxin Figure 3
Leptomycin B treatment causes nuclear accumulation of zyxin and results in co-localization of SIRT1 with 
zyxin. (A) COS-7 cells transfected with plasmids encoding HA-SIRT1 and GFP-zyxin were cultured for 24 h, in the presence 
or absence of 20 nM Leptomycin B during the last 6 h. Cells were stained with anti-Myc. Bars, 20 μm. (B) Confocal images 
show colocalization of SIRT1 and zyxin in nucleus in the presense of LMB. Bar, 10 μm. (C) Zyxin localization was classified in 
COS-7 cells expressing HA-SIRT1 and GFP-zyxin. "Cytoplasm" indicates COS-7 cell exhibiting GFP-zyxin only in the cytosol. 
"Nucleus" indicates COS-7 cell exhibiting nuclear-accumulated GFP-zyxin. Results (%) are the mean ± SD from three independ-
ent experiments.
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Interaction of SIRT1 with zyxin in mammalian cells Figure 4
Interaction of SIRT1 with zyxin in mammalian cells. (A, B) Co-immunoprecipitation of SIRT1 and zyxin HEK293T cells 
transiently transfected with the indicated plasmids and treated with 20 nM of leptomycin B (LMB) for 6 h. Cell lysates were 
immunoprecipitated with the anti-GFP antibody (A) or anti-HA antibody (B). The immunoprecipitates were immunoblotted 
with a reciprocal antibody. (C) Endogenous SIRT1 interacts with GFP-zyxin. The lysates of HEK293T cells expressing GFP-
zyxin were immunoprecipitated with anti-SIRT1 antibody or mouse IgG. The immunoprecipitates were immunoblotted with 
anti-GFP antibody.BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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Relative expression levels of SIRT1 and zyxin mRNA in various mouse tissues and developmental stages Figure 5
Relative expression levels of SIRT1 and zyxin mRNA in various mouse tissues and developmental stages. (A) 
Quantitative real-time PCR expression profiles of mouse cDNA from different tissues. The expression levels of SIRT1 and 
zyxin relative to those of GAPDH were assessed by ΔΔCt method. Results are the mean ± S.E from three independent reac-
tions. (B) Real-time PCR expression profiles of mouse cDNA from whole brain at different developmental stages. The expres-
sion levels of SIRT1 and zyxin mRNA are represented as relative fold as compared with the value in brain(A) and P1(B). E13, 
15, 17; Embryonic day 13, 15, 17. P1, P2w, P4w: Post natal day 1, 2 weeks, 4 weeks.
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GFP antibody was incubated in the reaction buffer con-
taining bacterially expressed GST-SIRT1, in the presence
of NAD+ or SIRT1 inhibitor, nicotinamide (NAm). The
samples were resolved on a SDS-PAGE, and the acetyla-
tion status was monitored by immunoblotting with anti-
Ac-Lys antibody, a specific antibody for acetylated lysine.
As shown in Figure 6A, the signals for acetylated GFP-
zyxin decreased in an NAD+-dependent manner; this was
abolished in the presence of NAm. These results indicate
that SIRT1 can deacetylate zyxin directly in an NAD+-
dependent manner in vitro.
We next examined whether SIRT1 mediates the deacetyla-
tion of zyxin in vivo. COS-7 cells were co-transfected with
SIRT1 deacetylates zyxin in vitro and in vivo Figure 6
SIRT1 deacetylates zyxin in vitro and in vivo. (A) SIRT1 deacetylates zyxin in vitro. GFP-zyxin, immunoprecipitated using 
anti-GFP antibody, was added with recombinant GST-SIRT1 in the presence or absence of NAD or nicotinamide (NAm). The 
acetylation levels of zyxin were determined using anti-acetylated lysine antibody. (B) SIRT1 deacetylates zyxin in mammalian 
cells. COS-7 cells were transfected with plasmids expressing GFP-zyxin and Myc-SIRT1 and incubated for 6 h in the presence 
or absence of leptomycin B. GFP-Zyxin was immunoprecipitated with anti-GFP antibody, and the acetylation levels of zyxin 
were determined using anti-acetylated lysine antibody. (C) SIRT1 H363Y does not affect the acetylation levels of zyxin. COS-7 
cells were transfected with plasmids expressing GFP-zyxin and Myc-SIRT1 H363Y. GFP-Zyxin was immunoprecipitated with 
anti-GFP antibody, and the acetylation levels of zyxin were determined using anti-acetylated lysine antibody. (D) HEK 293T 
cells expressing GFP-zyxin were treated for 24 h in the presence or absence of NAm. GFP-zyxin was immunoprecipitated 
using GFP antibody, and the acetylation levels of zyxin were determined using anti-acetylated lysine antibody.BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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expressing plasmids encoding Myc-tagged SIRT1 and GFP-
zyxin in the presence or absence of LMB, and cell lysates
were immunoprecipitated with anti-GFP antibody fol-
lowed by Western blot analysis using anti-Ac-Lys antibody
to monitor acetylation levels. As shown in Figure 6B, the
signals for acetylated GFP-zyxin were remarkably reduced
in the presence of Myc-tagged SIRT (first panel, lanes 2
and 4) as compared with the control (first panel, lanes 1
and 3), suggesting that SIRT1 can deacetylate zyxin in vivo.
The signals for acetylated GFP-zyxin without LMB treat-
ment are stronger as compared to those with LMB treat-
ment (Figure 6B, first panel), while the amounts of total
GFP-zyxin protein in immunoprecipitates are comparable
(Figure 6B, second panel). This suggests that SIRT1 could
deacetylate nuclear-accumulated zyxin. To confirm the
specificity of deacetylation by SIRT1, we performed an in
vivo  deacetylation assay using SIRT1 H363Y, a loss-of-
function mutant [6,9]. The signals for acetylated GFP-
zyxin were remarkably enhanced by SIRT1 H363Y overex-
pression (Figure 6C), indicating the specificity for
deacetylation by SIRT1. To strengthen this result, we then
examined the effect of SIRT1 inhibitor, nicotinamide
(NAm), in an in vivo deacetylation assay. HEK293T cells
were transfected with plasmids expressing GFP-zyxin,
with or without NAm treatment for 24 h, and GFP-zyxin
was immunoprecipitated with anti-GFP antibody. The
deacetylation levels were monitored by a Western blot
analysis with anti-Ac-Lys antibody. The signals for
acetylated GFP-zyxin were remarkably enhanced in the
presence of NAm (Figure 6D), indicating the specificity of
deacetylation by SIRT1. Taken together, these results
clearly show that in mammalian cells, SIRT1 can modu-
late the deacetylation levels of zyxin, most likely in the
nucleus.
Discussion
The present study shows that zyxin is a novel interacting
partner for SIRT1. SIRT1 and zyxin are co-localized in the
nucleus after LMB treatment, suggesting that nuclear-accu-
mulated zyxin interacts with SIRT1. SIRT1 and zyxin tran-
script are both preferentially expressed in developing
mouse brain and various adult tissues, including lungs,
spleen, and testis. Furthermore, SIRT1 deacetylates zyxin,
especially after LMB treatment, raising the possibility that
SIRT1 could modulate zyxin's functions in the nucleus via
deacetylation. Zyxin-null mice exhibit almost no abnor-
mal phenotype, probably due to genetic redundancy [31].
On the other hand, SIRT1-null mice show growth retarda-
tion and developmental defects in various tissues [12,13],
which suggests a critical role of SIRT1 in the developmen-
tal stage. Based on these reports, our data could raise the
possibility that zyxin is one of the downstream effectors
necessary for SIRT1 to execute some biological functions
in the developing brain and various adult tissues.
There is an apparent contradiction between the yeast and
mammalian results. Apparently SIRT1 does not bind to
full length zyxin in yeast because of some hypothesized
masking of the LIM3. However, the mammalian cell
experiments do show apparent association between full-
length zyxin and SIRT1. As mentioned above, a previous
study showed that full-length zyxin interacts with h-warts/
LATS1 in vivo but not in vitro, raising the possibility that
LIM1/2 domains are masked in full-length zyxin and
some modification might be critical for their interaction
[22]. Therefore we also hypothesize some modification
would be required for full-length zyxin to bind to SIRT1
in mammalian cells.
Then what is the biological function of the interaction
between SIRT1 and zyxin? Cell survival effect is one of the
features shared by these proteins. SIRT1 can protect neu-
rons from oxidative stress in mammalian cells [32], neu-
rotoxicity in cell-based models for AD/tauopathies, ALS
[16], and Wallerian degeneration [14]. SIRT1 expression
levels are induced in mouse models of neurodegeneration
[16], and moderate heart-specific overexpression of SIRT1
in mice delays aging of the heart by conferring resistance
to oxidative stress [33]. On the other hand, nuclear-accu-
mulated zyxin can protect cardiomyctes from oxidative
stress [28]. These reports raise the possibility that the
interaction of these proteins could be implicated in cellu-
lar survival, especially in the brain and heart, during phys-
iological senescence. Since zyxin could affect
transcriptional activity [27] and since nuclear-accumu-
lated zyxin executes anti-apoptotic function cooperating
with Akt in the nucleus [28], it is possible SIRT1 could
modulate these functions of zyxin via deacetylation. Con-
sidering that SIRT1-null mice exhibit developmental
defects with frequent exencephaly and retinal phenotype
with abnormal proliferation [12,13], it is possible that the
interaction of these proteins could be implicated in cellu-
lar survival pathways in the developmental stage.
In addition, shuttling between the cytosol and the nucleus
is a characteristic feature shared by SIRT1 and zyxin. In
this study, it was not determined whether the acetylation
status of zyxin affects its cellular localization or whether
deacetylated zyxin is retained in the nucleus. Recently, it
was reported that nuclear zyxin, phosphorylated by Akt,
interacts with acinus-S to prevent apoptosis and 14-3-3γ
plays a pivotal role in the nuclear translocation of zyxin
[29]. The morphological studies in the present study show
that zyxin is localized primarily in the cytosol with puncta
and it accumulates in the nucleus only with the LMB treat-
ment, but not with insulin-like growth factor (IGF-1) or
LY294002 treatment, an inhibitor of PI 3-kinase, in COS-
7 cells (data not shown). This suggests that some
unknown stimuli other than the IGF-1-Akt-related path-
way could play a critical role for zyxin to translocate intoBMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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the nucleus. The nuclear accumulation of zyxin is not
induced by co-expression with SIRT1, suggesting that it is
unlikely SIRT1 enhances the accumulation and/or trans-
location of zyxin into the nucleus. Since the sub-cellular
localization of SIRT1 differs based on cell type and differ-
entiation [12,32-34], it is possible that SIRT1 could inter-
act with zyxin in the cytosol depending on the cell type
and differentiation.
ECM, beyond scaffolding functions, is responsible for
transmitting environmental signals into cells, thereby
essentially affecting all aspects of cell life, including its
proliferation, differentiation, and death [35]. Since zyxin
is considered to convey signals from ECM into the nucleus
at the focal adhesion plaques, we now assume that SIRT1
could regulate the signal transmission from ECM into the
nucleus by modulating zyxin's functions via deacetyla-
tion, thereby reflecting its biological functions.
Finally as described in above, several functional signifi-
cances could be assumed for the interaction, including the
cell survival effect especially in development and/or regu-
lation of signal transmission from ECM into the nucleus.
Actually we had performed experiments to investigate
whether the interaction of these proteins could affect the
apoptosis under stress condition or the transcriptional
activity of zyxin in luciferase reporter gene assay (data not
shown). Thus far, we could not obtain the result to indi-
cate the biological significance of the interaction in such
simple systems. Additional experiments are required to
clarify the functional significance of the interaction in the
future.
Conclusion
In conclusion, zyxin could be a novel interacting partner
of SIRT1. Zyxin is an adaptor protein at focal adhesion
plaque, regulating cytoskeletal dynamics and signal trans-
duction to convey signal from the ECM (extracellular
matrix) to the nucleus. Our results raise the possibility
that SIRT1 regulates signal transmission from ECM to the
nucleus by modulating the functions of zyxin via
deacetylation.
Methods
Cell culture and transfection
Human embryonic kidney cell line HEK 293T cells and
African green monkey kidney fibroblast like cell line COS-
7 cells were cultured in DMEM (Gibco) supplemented
with 10% fetal bovine serum (FBS) and antibiotics (50 U
penicillin-streptomycin) at 37°C in a 5% CO2 atmos-
phere inside a humidified incubator. Transient transfec-
tion was performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instructions.
Plasmid constructs
The FLAG-tagged mammalian expression vectors encod-
ing wild-type (wt) human SIRT1 or a mutant catalytically
inactive SIRT1 [6], SIRT1 H363Y, were obtained from
Addgene (USA). The mammalian expression vectors
encoding the Myc-tagged form of human SIRT1 were gen-
erated by sub-cloning from SIRT1 wt or SIRT1 H363Y
cDNA fragments into the Sac1-Sal1 site of the pMyc-C1
mammalian expression vector containing the Myc epitope
tag [36]. SIRT1 wt cDNA were sub-cloned into pGEX-6P-3
(GE Healthcare) for bacterial GST fusion expression.
pEGFP-C1-zyxin was provided by Dr. Saya (Kumamoto
University School of Medicine, Japan). For the pull-down
assay, cDNA fragments encoding full-length and deletion
mutants of zyxin (as illustrated in Figure 2A) were ampli-
fied by PCR from pEGFP-zyxin and sub-cloned into pHA-
C1 mammalian expression vector containing the HA
epitope tag [36]. All constructs were verified by DNA
sequencing.
Antibodies
Monoclonal anti-HA (HA-7; Sigma-Aldrich), anti-c-Myc
(9E10; Santa Cruz Biotechnology, Inc.), and anti-SIRT1
(2G1/F7; Upstate), polyclonal anti-Acetylated lysine (Cell
Signaling technology) were used.
Yeast two-hybrid screening
Yeast two-hybrid screening was conducted using Match-
maker GAL4 two-hybrid system 3 (Clontech). The region
containing the deacetylation domain of SIRT1 (amino
acid (aa) 185–505) was generated by PCR, subcloned
downstream of the GAL4 DNA-binding domain in
pGBKT7, and introduced into the yeast strain AH109 as
bait. The human fetal brain cDNA library in pGADT7 was
introduced into the yeast strain Y187. These two yeast
strains were combined according to the yeast mating pro-
tocol recommended by the manufacturer. Diploid cells
were screened for growth on SD agar plates lacking ade-
nine, histidine, leucine, and tryptophan (4 drop out).
To confirm the yeast two-hybrid assay results, the yeast
strain AH109 was retransformed with pGBKT-SIRT1/bait
(aa 185–505 of SIRT1) and histidine and adenine positive
clones. Then, the positive clones were further evaluated
for beta-GAL expression by colony-lift filter assay.
The plasmids were isolated from a colony showing beta-
GAL activity using an alkaline solution (3% SDS, 0.2 M
NaOH), transformed into bacteria by heatshock or elec-
troporation, and then DNA sequenced. The clones encod-
ing the partial protein fragments of zyxin were
determined.BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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Pull-down assay
Transiently transfected HEK 293T cells were lysed with a
lysis buffer (0.5% NP-40, 20 mM HEPES, 150 mM NaCl,
1 mM EDTA, protease inhibitor cocktail (Roche)). Cell
lysates were pre-cleared with GST immobilized on glu-
tathione-sepharose 4B (GE Healthcare) for 1 h. GST
fusion protein (10 μg) was immobilized on glutathione-
sepharose beads at 4°C for 4 h. Then the glutathione-
sepharose beads were incubated with cell lysate in 500 μL
of the lysis buffer for 4 h at 4°C. After washing with a
wash buffer (0.1% NP-40, 20 mM HEPES, 150 mM NaCl,
1 mM EDTA), the bound proteins were eluted by boiling
for 5 min in a sample buffer (50 mM Tris-HCl (pH 6.8),
2% SDS, 8% glycerol, 4% mercaptoethanol, 0.04%
bromophenol blue), and analyzed by western blot analy-
sis.
RNA extraction, reverse transcription, and real-time PCR
Isolated mouse brains at various ages and various normal
tissues were flash-frozen in liquid nitrogen and stored at -
80°C until RNA purification. Total RNA was extracted
using Trizol (Invitrogen) according to the manufacturer's
instructions. RNA (2 μg) was reverse transcribed to pro-
duce cDNA using Ready-To-Go RT-PCR beads (GE
Healthcare).
Real-time PCR was performed using SYBR GreeenER
qPCR SuperMis for ABI PRISM (Invitrogen). All real-time
PCR assays were performed in triplicate using a 7300 Real-
Time PCR System (Applied Biosystems) as follows: 50°C
for 2 min, 95°C for 10 min, 40 cycles at 95°C for 20 s and
at 60°C for 1 min. Primers for the mouse Sir2α (SIRT1)
mRNA were designed as described previously [34]. Prim-
ers for mouse zyxin were designed using Primer Express
version 3.0 (Applied Biosystems). For standardization of
relative mRNA expression, rodent GAPDH primers were
used. The specificity of each primer set was determined
with a pre-test showing the specific amplification for a
specific gene by gel visualization and sequencing. The
results of cycle threshold values (Ct values) were calcu-
lated by the ΔΔCt method to obtain the fold differences.
Immunofluorescence
COS-7 cells transfected with plasmids encoding GFP-
zyxin and/or HA-SIRT1 were cultured for 42 h and treated
with or without Leptomycin B (LMB) for the next 6 h.
Then, the cells were fixed with 4% paraformaldehyde for
1 h and then rehydrated by PBS. Cells were permeabilized
and non-specific sites were blocked by incubating with
PBS containing 0.5% Triton X-100 and 5% bovine serum
albumin (BSA). The cells were incubated with antibodies
diluted in a blocking solution for 1 h at 4°C. Then, the
cells were washed in PBS and incubated with secondary
antibodies, Alexa fluor, for 1 h at room temperature. After
immuno staining, the slides were mounted with a fluores-
cent mounting medium (DakoCytomation). Confocal
images were obtained using a Fluoview FV1000 (Olym-
pus) laser scanning microscope. XZ and YZ sections were
created when all Z-series sections at 0.50 μm intervals
were merged.
Immunoprecipitation
HEK293T cells were transfected with plasmids encoding
GFP-zyxin and/or HA-SIRT1 using Lipofectamine 2000
reagent as previously described. The transfected cells were
cultured for 42 h and treated with or without leptomycin
B (LMB) for the next 6 h. To immunoprecipitate the
expressed GFP-tagged proteins, the cells were lysed in a
lysis buffer (0.5% NP-40, 20 mM HEPES (pH 8.0), 150
mM NaCl, 1 mM EDTA, protease inhibitor cocktail
(Roche)). The whole-cell lysates were pre-cleared with
rProtein A sepharose Fast Flow (GE Healthcare) at 4°C for
1 h. The supernatants were incubated at 4°C for 4 h with
anti-GFP antibody or anti-HA antibody and rProtein A
sepharose. After washing three times in a wash buffer, the
immunoprecipitates were boiled in a sample buffer con-
taining 12% beta-mercaptoethanol for 5 min and sub-
jected to western blot analysis.
Western blot analysis
Western blot analysis was modified as described previ-
ously [37]. In brief, cell lysates or immunoprecipitated
proteins were separated on SDS-PAGE and transferred
onto polyvinylidene difluoride membranes (Millipore).
The membrane was blocked with 5% nonfat dry milk in
PBS containing 0.05% Tween 20 (PBS-T) and incubated
for 2 h at room temperature with the first antibody diluted
in PBS-T containing 1% nonfat dry milk. After washing
with PBS-T, the membrane was incubated with horserad-
ish peroxidase-linked anti-mouse IgG antibody or anti-
rabbit IgG antibody (Cell Signaling Technology). For
detection, an ECL chemiluminescence system (GE Health-
care) was used.
Deacetylation assay
For the in vitro deacetylation assay, zyxin was immunopre-
cipitated and incubated with GST-SIRT1. The deacetyla-
tion reaction was performed as reported previously [38].
COS-7 or HEK293T cells were transfected with plasmids
encoding GFP-zyxin and/or Myc-SIRT1. The cells were cul-
tured for 48 h in the presence or absence of LMB during
the last 6 h. The cells were lysed with an RIPA buffer (20
mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.1%
SDS, 1% Triton X-100, 1% sodium deoxycholate, protease
inhibitor cocktail (Roche)). Lysates were immunoprecipi-
tated with anti-GFP antibody and the acetylation levels of
zyxin were detected by anti-acetylated lysine antibody.BMC Cell Biology 2009, 10:6 http://www.biomedcentral.com/1471-2121/10/6
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